Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any autosomal agammaglobulinemia in which the cause of the disease is a mutation in the BLNK gene.
Features include always present findings: Decreased circulating total IgM, Protein-losing enteropathy, Chronic sinusitis, and Recurrent bacterial infections and others; and common findings: Decreased total neutrophil count. 11 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 2 | Recurrent bacterial infections, Decreased total neutrophil count |
BLNK encodes B cell linker (456 aa). Functions as a central linker protein, downstream of the B-cell receptor (BCR), bridging the SYK kinase to a multitude of signaling pathways and regulating biological outcomes of B-cell function and development. Highest expression in Cells EBV-transformed lymphocytes (202.8 TPM) and Spleen (80.5 TPM).
Agammaglobulinemia 4, autosomal recessive is caused by mutations in the BLNK gene on chromosome 10.
The BLNK protein participates in BLNK (SLP-65) Signalosome pathway.
BLNK is classified as a druggable target (Kinase category) with score 0.0.
Genetic testing for BLNK is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 8 always present features, 1 common feature.
No clinical trials have been registered for agammaglobulinemia 4, autosomal recessive.
7 publications have been identified in PubMed for agammaglobulinemia 4, autosomal recessive. Research spans Case Report / Case Series (57%), Clinical Trial Publication (14%), and Basic Science / Preclinical (14%).
Kose H (2025). [PMID: 40546005](https://pubmed.ncbi.nlm.nih.gov/40546005/). *Iranian journal of immunology : IJI*. [Case Report / Case Series]
Boyarchuk O (2025). [PMID: 40443574](https://pubmed.ncbi.nlm.nih.gov/40443574/). *Frontiers in pediatrics*. [Case Report / Case Series]
Özdemiral C (2025). [PMID: 40862510](https://pubmed.ncbi.nlm.nih.gov/40862510/). *Journal of medical virology*. [Epidemiology / Natural History]
Yang YH (2024). [PMID: 39413134](https://pubmed.ncbi.nlm.nih.gov/39413134/). *Proceedings of the National Academy of Sciences of the United States of America*. [Case Report / Case Series]
Tekcan D (2024). [PMID: 39607724](https://pubmed.ncbi.nlm.nih.gov/39607724/). *Pediatric allergy, immunology, and pulmonology*. [Clinical Trial Publication]
Data assembled from 6 of 12 sources · Last updated Sep 20, 2026, 5:51 AM UTC
Online Mendelian Inheritance in Man
Genetic and Rare Diseases Info Center
Common questions about agammaglobulinemia 4, autosomal recessive
Ears |
1 |
Recurrent otitis media |
Lungs and breathing | 1 | Recurrent pneumonia |
Marakhonov AV (2024). [PMID: 38578360](https://pubmed.ncbi.nlm.nih.gov/38578360/). *Journal of clinical immunology*. [Basic Science / Preclinical]
Naiboğlu S (2024). [PMID: 39549297](https://pubmed.ncbi.nlm.nih.gov/39549297/). *Iranian journal of allergy, asthma, and immunology*. [Case Report / Case Series]